Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 million BackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation in the second half of 2023 in collaboration with Medtronic Virtue SAB® U.S. pivotal study in coronary in-stent restenosis (“ISR”) start planned for […]
Other News
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commercial launch preparations continue in China, supported by the promotion of Pascal Qian to Chief Commercial Official Cash, cash equivalents […]
HeartBeam Reports First Quarter 2023 Financial Results
Closed $26.5 Million with a Public Offering and Registered Direct Offering to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones and Extend Cash Runway into Late 2024 Strategic Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Management to Host Webcast […]
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, 2023. Business Updates Announced the appointment of Gansevoort “Gan” Dunnington, MD, as Chief […]
ConcertAI’s TeraRecon Advances Cardiovascular Visualization with the Launch of Intuition 4.7
State-of-the-art structural heart capabilities simplify pre-op planning for interventional clinicians through automated workflows and enhanced interoperability CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ — ConcertAI’s TeraRecon, the advanced visualization (AV) and clinical AI SaaS category leader, today announced the global launch of its flagship, best-in-KLAS advanced visualization product, Intuition 4.7. A dedicated structural heart […]
Merck Manuals Breaks Down Differences Between Heart Attack and Cardiac Arrest
Doctor outlines key distinctions and how to respond to both conditions RAHWAY, N.J., May 10, 2023 /PRNewswire/ — The terms “heart attack” and “cardiac arrest” are often used interchangeably. In reality, they are distinct, typically with different causes and requiring different responses in the moment to get the person the help they […]
PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) – A RARE, LIFE-THREATENING DISEASE
KUALA LUMPUR, Malaysia, May 11, 2023 /PRNewswire/ — In an effort to encourage people to take care of their heart health, Pfizer Malaysia is calling for Malaysians to learn more about transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening disease. ATTR-CM is caused by unstable transthyretin proteins that misfold and aggregate into amyloid […]
CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting
The company confirms its sales target of €10-13 million for 2023 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, informs its shareholders that the Combined General […]
Semler Scientific Reports First Quarter 2023 Financial Results
2023 Q1 highlights: Revenue was $18.2 million, an increase of 30% compared to the corresponding period of 2022 Net income was $5.0 million, an increase of 48% compared to the corresponding period of 2022 Cash, cash equivalents and short-term investments of $43.0 million SANTA CLARA, Calif., May 10, 2023 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), […]
Foldax, Inc. Receives Full Ownership Rights to Proprietary Polymer Patent Portfolio
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® Inc. today announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full ownership of a polymer technology patent family. Foldax has incorporated the polymer technology into its LifePolymer™ materials platform and has conducted testing, which indicates the materials are compatible with blood, with […]
Recent
Da Vinci 5 Cleared for Cardiac Procedures
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES
Popular
- No commented posts yet